Core Viewpoint - Nengte Technology (002102.SZ) is experiencing explosive growth in performance, with a projected net profit of 330 million to 380 million yuan for the first half of 2025, representing a year-on-year increase of 480.15% to 568.05% [1][2] Financial Performance - The expected net profit for the first half of 2025 is significantly higher than the previous year's 56.88 million yuan, indicating a growth rate of 480.15% to 568.05% [2] - The net profit after excluding non-recurring gains and losses is projected to be between 400 million and 450 million yuan, a staggering increase of 736.44% to 840.66% compared to last year's 47.82 million yuan [2] - Basic earnings per share are expected to rise from 0.0216 yuan to between 0.1253 and 0.1443 yuan [2] - In Q1 2025, the company achieved an operating income of 2.877 billion yuan, a decrease of 5.38% year-on-year, but the net profit attributable to shareholders increased by 287.20% to 216 million yuan [3] Business Segments - The vitamin E and pharmaceutical intermediates business of the wholly-owned subsidiary Nengte Technology Co., Ltd. is the main contributor to the company's profits, generating over 440 million yuan [2] - The subsidiary has developed into a high-tech enterprise focusing on pharmaceutical intermediates and vitamin E, with key products including montelukast sodium intermediates for asthma treatment and rosuvastatin intermediates for hyperlipidemia treatment [2] Strategic Transformation - The company's performance surge is attributed to its ongoing strategic transformation, which began after the acquisition by Jingzhou City Development Group in 2022 [4] - Since rebranding to Nengte Technology in April 2024, the company has been divesting non-core assets and focusing on pharmaceuticals and vitamin E [4] - In 2024, the company faced a net loss of 489 million yuan due to the underperformance of its plastic trade e-commerce business, which included a goodwill impairment of 591 million yuan [4] Share Buyback and Future Projects - To boost market confidence, the company announced a share buyback plan of 300 million to 500 million yuan, with a maximum buyback price of 3.90 yuan per share [4] - As of the end of Q1, the company had repurchased 98.82 million shares, accounting for 3.75% of the total share capital, using 330 million yuan [4] - The subsidiary is accelerating the construction of new projects, including a 350 million yuan project for an annual production of 100,000 tons of chemical recycling polyester and a 50 million yuan project for an annual production of 100 tons of boswellic acid, which are expected to generate significant net profits upon completion [5]

根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》等相关规定，现将公司 2025 年第五次临时股东大会的股 权登记日（2025 年 7 月 11 日）登记在册的前十名股东和前十名无限售条件股东 的名称、持股数量及比例公告如下： 1 序号 股东名称 持股数量 （股） 占总股本 比例 1 湖北荆江实业投资集团有限公司 338,463,100 12.86% 2 陈烈权 232,163,822 8.82% 3 邓海雄 178,674,857 6.79% 4 北京天宇泽华物联科技有限公司 57,550,100 2.19% 5 汕头市金塑投资咨询中心（有限合 伙） 37,013,101 1.41% 6 刘飞达 35,813,420 1.36% 7 中信证券－中信银行－中信证券卓越 成长两年持有期混合型集合资产管理 计划 31,543,900 1.20% 8 荆州市古城国有投资有限责任公司 31,190,500 1.18% 9 刘文强 24,760,000 0.94% 一、公司前十名股东持股情况 | | | 证券代码：002102 证券简称：能特科技 公告编号：2025-076 湖北 ...

[Hubei Net Technology Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=Hubei%20Net%20Technology%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Forecast) [Current Period Performance Forecast](index=1&type=section&id=Current%20Period%20Performance%20Forecast) The company expects to turn losses into profits in the first half of 2025, with net profit attributable to shareholders estimated between 330 million yuan and 380 million yuan, representing a year-on-year growth of 480.15% to 568.05% [Performance Forecast Period](index=1&type=section&id=Performance%20Forecast%20Period) This performance forecast covers the period from January 1, 2025, to June 30, 2025 - The performance forecast covers the first half of 2025, specifically from January 1, 2025, to June 30, 2025[3](index=3&type=chunk) [Performance Forecast Details](index=1&type=section&id=Performance%20Forecast%20Details) During the reporting period, the company expects significant growth in both net profit attributable to shareholders and non-recurring net profit, with basic earnings per share increasing from 0.0216 yuan/share in the same period last year to 0.1253 yuan/share to 0.1443 yuan/share Key Data from 2025 Semi-Annual Performance Forecast | Item | Current Reporting Period | Prior Year Same Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | **Profit: 330.00 million yuan ~ 380.00 million yuan** | Profit: 56.88 million yuan | | | Year-on-year growth: **480.15% - 568.05%** | | | **Net Profit After Deducting Non-Recurring Gains and Losses** | **Profit: 400.00 million yuan ~ 450.00 million yuan** | Profit: 47.82 million yuan | | **Basic Earnings Per Share** | **Profit: 0.1253 yuan/share ~ 0.1443 yuan/share** | Profit: 0.0216 yuan/share | [Communication with Accounting Firm](index=1&type=section&id=Communication%20with%20Accounting%20Firm) The company explicitly states that the financial data in this performance forecast are preliminary estimates by the finance department and have not yet been audited by a certified public accountant - The data in this performance forecast are preliminary estimates by the company's finance department and have not been audited by a certified public accountant[4](index=4&type=chunk) [Explanation of Performance Change](index=1&type=section&id=Explanation%20of%20Performance%20Change) The significant performance growth is primarily driven by the wholly-owned subsidiary, Net Technology Co., Ltd., whose strong performance in Vitamin E and pharmaceutical intermediate businesses is expected to contribute no less than 440 million yuan in profit to the company - Performance growth is primarily attributed to the Vitamin E and pharmaceutical intermediate businesses of the wholly-owned subsidiary, Net Technology Co., Ltd., which are expected to contribute no less than **440 million yuan** in profit[5](index=5&type=chunk) [Risk Warning](index=2&type=section&id=Risk%20Warning) The company reminds investors that this forecast is a preliminary estimate, and the final accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, advising investors to be aware of investment risks - The company advises that this performance forecast is a preliminary estimate, and the final data will be based on the 2025 semi-annual report, urging investors to make cautious decisions[6](index=6&type=chunk)

能特科技（002102）公告，预计2025年1月1日至2025年6月30日归属于上市公司股东的净利润为3.3亿元 ～3.8亿元，比上年同期的5688.18万元增长480.15%-568.05%。扣除非经常性损益后的净利润为4亿元～ 4.5亿元，比上年同期的4782.33万元有所增长。基本每股收益为0.1253元/股～0.1443元/股。业绩增长主 要由全资子公司能特科技有限公司的维生素E及医药中间体业务经营良好所推动，预计为公司带来不低 于4.4亿元的利润。 ...

Policy Developments - The Ministry of Finance announced measures regarding government procurement of medical devices imported from the EU, stating that for medical devices with a procurement budget of over 45 million yuan, EU companies (excluding EU-funded enterprises in China) must be excluded from participation if imported products are required [2] Drug and Device Approvals - Weikang Pharmaceutical's Anruini capsules have been submitted for market approval, intended for adult and adolescent patients with solid tumors carrying NTRK fusion genes [3] - AstraZeneca's Imfinzi (Durvalumab) has been approved in the EU for use in muscle-invasive bladder cancer (MIBC) as a neoadjuvant treatment in combination with Gemcitabine and Cisplatin, followed by monotherapy after radical cystectomy [4] Capital Markets - Micot completed a D-round financing exceeding 100 million yuan, led by Zhejiang Merchants Venture Capital, with funds aimed at core pipeline development and the establishment of a formulation industrialization base [5] - Opcon Vision announced plans to use 334 million yuan to acquire 75% of Jiangsu Shangyue Qicheng Hospital Management Co., with part of the funds originally allocated for community optical service terminal construction [6] Industry Developments - Tengsheng Bo Pharmaceutical has reached a BD licensing agreement with Health Yuan for BRII-693, with Health Yuan responsible for its development and commercialization in Greater China [8] - Sunshine Nuohong signed a technical development cooperation contract with Shanghai Lekuang Huilin Pharmaceutical Technology for the STC007 project, with a total milestone payment of 200 million yuan [7] Public Sentiment Alerts - Nengte Technology adjusted the listing price for the 100% equity transfer of its subsidiary, Ankang Shenqian Mining Co., to 114 million yuan, a 15% decrease from the previous listing price [9] Shareholder Actions - Ever Union (H.K.) Limited, a shareholder of Mindray Medical, plans to reduce its stake by up to 5 million shares, representing approximately 0.41% of the company's total share capital [10][11]

证券代码：002102 证券简称：能特科技 公告编号：2025-074 本次交易已经公司 2025 年 4 月 24 日召开的第七届董事会第三十一次会议审 议通过，无需获得股东大会的批准。公司董事会同意授权公司管理层按照《企业国 有资产交易监督管理办法》《企业国有资产交易操作规则》等相关法律法规的规定 办理公开挂牌转让燊乾矿业 100%股权的具体事宜。如未能征集到符合条件的交易 对手方或最终未能成交，具体由公司董事会及董事会授权人根据市场情况及公司 实际情况决定。具体内容详见公司于 2025 年 4 月 26 日、2025 年 6 月 6 日、2025 年 6 月 14 日披露的《关于公开挂牌转让全资子公司陕西省安康燊乾矿业有限公司 湖北能特科技股份有限公司 关于公开挂牌转让全资子公司 陕西省安康燊乾矿业有限公司 100%股权的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 湖北能特科技股份有限公司（以下简称"公司"）在武汉光谷联合产权交易所 荆州产权交易有限公司（以下简称"荆州产交所"）公开挂牌转让公司之全资子公 司陕西省安康燊乾矿业有 ...

Group 1 - Shengde Xintai won a bid for a thermal power steel pipe project worth approximately 217 million yuan, accounting for 8.15% of its audited revenue for 2024 [1] - High-speed Electric's subsidiary won a project for the Shanghai-Nanjing-Hefei high-speed railway, with a bid amount of 71.76 million yuan [1] - Cangge Mining's subsidiary received a construction permit for a lithium-boron mining project, with a construction area of 106,900 square meters [2] Group 2 - China Electric Power Construction signed a mining transportation project contract in Guinea worth approximately 5.063 billion yuan, with a total duration of about 72 months [3] - Guobang Pharmaceutical's subsidiary completed the registration of an equity investment fund focusing on strategic emerging industries [4] - Deshi Co. obtained two invention patents related to oil and gas field development [5][26] Group 3 - Xue Tian Salt Industry expects a significant decrease in net profit for the first half of 2025, projecting a decline of 76.34% to 80.29% [6] - Rundu Co. received a drug registration certificate for moxifloxacin hydrochloride tablets, used for treating various bacterial infections [7] - China Nuclear Power reported a 15.65% increase in power generation in the first half of the year, with nuclear power generation up by 12.01% [8] Group 4 - Suqian Liansheng obtained two invention patents related to wastewater treatment methods [9] - Boshi Co. signed a 109 million yuan operation and maintenance service contract for solid product packaging [11] - *ST Sailong's subsidiary received a drug registration certificate for torasemide injection, used for various medical conditions [13] Group 5 - North Bay Port reported a 10.95% increase in cargo throughput for the first half of 2025, with container throughput also showing growth [14] - Kaiwei Te expects a revenue increase of 56.17% to 90.87% for the first half of 2025 [15] - Wankai New Materials plans to reduce production and conduct maintenance on 60,000 tons of PET capacity, affecting overall performance [16] Group 6 - Haiwang Bio's HW130 injection successfully completed Phase I clinical trials, showing good safety and tolerability [19] - Zhenai Meijia received a total of 22.8 million yuan in compensation for land acquisition, which will significantly impact its 2025 performance [20] - Changyuan Electric reported a 23.58% decrease in power generation in June, with a notable decline in thermal power generation [21] Group 7 - Shouxiangu's subsidiary completed the registration of two health food products [22] - Kailun Co. announced the resignation of its deputy general manager and board secretary [23] - Xibu Muye reported a 2.15% year-on-year increase in fresh milk production in June [24] Group 8 - Deshi Co. obtained two invention patents related to oil and gas field development [26] - Jingwei Huikai plans to acquire a 12.44% stake in Nuo Si Micro for 149 million yuan [27] - Electric Alloy completed the registration of its subsidiary in Mexico [29] Group 9 - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of 2025 [30] - Guizhou Moutai repurchased approximately 3.38 million shares, accounting for 0.2692% of its total share capital [31][32] - Warner Pharmaceutical received approval for the listing application of a raw material drug for treating respiratory diseases [34] Group 10 - Yuan Dong Bio's independent director is under investigation for serious violations [35] - Dash Intelligent signed a contract for a smart project worth 11.88 million yuan [36] - Dayou Energy plans to transfer 586,500 tons of coal production capacity replacement indicators [37] Group 11 - Foton Motor reported a 150.96% increase in new energy vehicle sales in the first half of 2025 [39] - Renfu Pharmaceutical's shareholder plans to increase its stake by 1% to 2% [40] - Zongshen Power expects a net profit increase of 70% to 100% for the first half of 2025 [42] Group 12 - Yingboer plans to sell its wholly-owned subsidiary for 239 million yuan [44] - Changan Automobile reported a 1.59% increase in total vehicle sales in the first half of 2025 [46] - Fulian Precision signed a cooperation framework agreement with Sichuan Development Longmang [48] Group 13 - Nengte Technology plans to repurchase shares worth 300 million to 500 million yuan [50] - Longsoft Technology's controlling shareholder donated 3.43% of the company's shares [51] - Data Port's shareholders plan to reduce their holdings by up to 2% [52]

Market Performance - The hair medical concept sector rose by 2.34%, ranking 10th among concept sectors, with 19 stocks increasing in value, including JiuZhiTang which hit the daily limit, and TianEnKang, KangHui Pharmaceutical, and KangYuan Pharmaceutical which rose by 6.42%, 5.16%, and 4.55% respectively [1] - The top gainers in today's market include the fruit index at 4.73%, PCB concept at 3.27%, and AI mobile at 2.92%, while the military restructuring concept saw a decline of 1.49% [1] Capital Flow - The hair medical concept sector experienced a net inflow of 219 million yuan, with 11 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 10 million yuan. JiuZhiTang led with a net inflow of 172 million yuan, followed by ShuiYang Co., KangYuan Pharmaceutical, and NengTe Technology with net inflows of 34.25 million yuan, 21.05 million yuan, and 13.44 million yuan respectively [1] - In terms of capital inflow ratios, JiuZhiTang, ShuiYang Co., and KangHui Pharmaceutical had the highest net inflow rates at 33.17%, 6.81%, and 6.15% respectively [2] Stock Performance - JiuZhiTang saw a significant increase of 10.06% with a turnover rate of 7.62%, while ShuiYang Co. and KangYuan Pharmaceutical increased by 3.12% and 4.55% respectively [2] - Stocks such as *ST JinBi and AoYang Health experienced declines of 0.69% and 0.26% respectively, indicating some volatility within the sector [1][3]

证券代码：002102 证券简称：能特科技 公告编号：2025-073 湖北能特科技股份有限公司（以下简称"公司）于 2025 年 7 月 2 日召开第 七届董事会第三十三次会议和第七届监事会第二十六次会议，审议通过了《关 于回购股份并注销的议案》，具体内容详见公司于 2025 年 7 月 3 日披露的《关 于回购股份方案的公告》（公告编号：2025-071）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》等相关规定，现将董事会决议公告前一交易日（2025 年 7 月 2 日）登记在册的前十名股东和前十名无限售条件股东的名称、持股数量及 比例公告如下： 注：以上股东的持股数量为合并普通账户和融资融券信用账户后的持股数量。 1 序号 股东名称 持股数量 （股） 占总股本 比例 1 湖北荆江实业投资集团有限公司 338,463,100 12.86% 2 陈烈权 232,163,822 8.82% 3 邓海雄 178,674,857 6.79% 4 北京天宇泽华物联科技有限公司 57,550,100 2.19% 5 汕头市金塑投资咨询中心（有限合伙） 37,013,10 ...

Key Points - Jiangnan Water received a stake increase from Lianan Life Insurance, reaching 5.03% of total shares [3] - Yingboer plans to transfer 100% equity of Zhuhai Dingyuan for 239 million yuan to optimize asset structure [4] - Chengbang Co. warns that its stock price fluctuations are not aligned with its fundamentals, as it has seen five consecutive trading days of price increases [6] - Weimais intends to invest 190 million yuan into its subsidiary for a new electric drive assembly project [7] - Fosun Pharma's subsidiary received EU GMP certification for its production facilities, indicating compliance with EU standards [8] - Jingwei Huikai plans to acquire an additional 12.44% stake in Nosi Micro, increasing its control in the semiconductor sector [9] - ST Tongmai will remove its delisting risk warning starting July 4, while continuing other risk warnings [10] - ST Modern seeks to apply for the removal of other risk warnings but will maintain delisting risk warnings [11] - Luxshare Precision is planning to issue H-shares for listing on the Hong Kong Stock Exchange [12] - Hainan Highway intends to purchase a 51% stake in Hainan Jiaokong Petrochemical, which will become a subsidiary [13] - Jucheng Co. plans to transfer 1.25% of its shares through a price inquiry [14] Performance Highlights - Foton Motor reported a 150.96% year-on-year increase in new energy vehicle sales for the first half of the year [15] - Jiangling Motors achieved a total vehicle sales of 172,700 units in the first half, up 8.15% year-on-year [16] - Changan Automobile's sales reached 1.3553 million units in the first half, with new energy vehicle sales growing by 49.05% [17] - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of the year [18] - Jihong Co. anticipates a net profit increase of 55% to 65% for the first half of the year [19] - Nanjing Business Travel expects a net profit decrease of 67.4% to 78.27% for the first half of the year [20] - Madi Technology forecasts a net profit of 25 million to 27 million yuan, marking a turnaround from losses in the previous year [21] Major Contracts - Dash Intelligent signed a contract for an intelligent project worth 11.88 million yuan [22] - Jinyi Industrial won a bid for a 335 million yuan intercity railway materials procurement project [23] - Sichuan Road and Bridge signed a construction contract worth approximately 11.596 billion yuan [24] - Fulian Precision signed a cooperation framework agreement with Chuanfa Longmang for lithium battery material projects [26] Share Buybacks - Kweichow Moutai repurchased 72,000 shares in June, totaling 1.02 billion yuan [27] - Feiwo Technology plans to repurchase shares worth 25 million to 50 million yuan [28] - Nengte Technology intends to repurchase shares worth 300 million to 500 million yuan for capital reduction [29] - CATL has repurchased 6.641 million A-shares for a total of 1.551 billion yuan [30] Shareholding Changes - Renfu Pharmaceutical's shareholder plans to increase its stake by 1% to 2% [31] - Sanwei Xinan's shareholder intends to reduce its stake by up to 2% [33] - Data Port's shareholders plan to reduce their stakes by up to 2% [34] - Zhuzhou Design's controlling shareholders plan to reduce their stakes by up to 3% [35] - Tianji Co.'s controlling shareholders plan to reduce their stakes by up to 3% [36] - Anjisi's shareholders plan to reduce their stakes by up to 4% [37] Financing Activities - CITIC Securities received approval to issue up to 20 billion yuan in perpetual subordinated bonds [39]